<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30372687</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-6400</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Journal of Huntington's disease</Title><ISOAbbreviation>J Huntingtons Dis</ISOAbbreviation></Journal><ArticleTitle>Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>307</EndPage><MedlinePgn>297-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JHD-180309</ELocationID><Abstract><AbstractText>The polyglutamine (polyQ) diseases, such as Huntington's disease and the spinocerebellar ataxias, are characterized by the accumulation of elongated polyQ sequences (epolyQ) and mostly occur during midlife. Considering that polyQ disorders have not been selected out in evolution, there might be important physiological functions of epolyQ during development and/or reproduction. In a similar context, the physiological functions of neurodegeneration-associated amyloidogenic proteins (APs), such as &#x3b2;-amyloid in Alzheimer's disease and &#x3b1;-synuclein in Parkinson's disease, remain elusive. In this regard, we recently proposed that evolvability for coping with diverse stressors in the brain, which is beneficial for offspring, might be relevant to the physiological functions of APs. Given analogous properties of APs and epolyQ in terms of neurotoxic amyloid-fibril formation, the objective of this paper is to determine whether evolvability could also be applied to the physiological functions of epolyQ. Indeed, APs and epolyQ are similar in many ways, including functional redundancy of non-amyloidogenic homologues, hormesis conferred by the heterogeneity of the stress-induced protein aggregates, the transgenerational prion-like transmission of the protein aggregates via germ cells, and the antagonistic pleiotropy relationship between evolvability and neurodegenerative disease. Given that epolyQ is widely expressed from microorganisms to human brain, whereas APs are only identified in vertebrates, evolvability of epolyQ is considered to be much more primitive compared to those of APs during evolution. Collectively, epolyQ may be not only be important in the pathophysiology of polyQ diseases, but also in the evolution of amyloid-related evolvability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>PCND Neuroscience Research Institute, Poway, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamatsu</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugama</LastName><ForeName>Shuei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takenouchi</LastName><ForeName>Takato</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waragai</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Huntingtons Dis</MedlineTA><NlmUniqueID>101589965</NlmUniqueID><ISSNLinking>1879-6397</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058685" MajorTopicYN="N">Genetic Pleiotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017827" MajorTopicYN="N">Machado-Joseph Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020191" MajorTopicYN="N">Myoclonic Epilepsies, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="N">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Stress</Keyword><Keyword MajorTopicYN="N">amyloidogenic proteins (APs)</Keyword><Keyword MajorTopicYN="N">antagonistic pleiotropy</Keyword><Keyword MajorTopicYN="N">elongated polyQ (epolyQ)</Keyword><Keyword MajorTopicYN="N">evolvability</Keyword><Keyword MajorTopicYN="N">p53</Keyword><Keyword MajorTopicYN="N">polyQ binding protein 1 (PQBP1)</Keyword><Keyword MajorTopicYN="N">polyglutamine (polyQ)</Keyword><Keyword MajorTopicYN="N">transgenerational transmission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30372687</ArticleId><ArticleId IdType="pmc">PMC6294593</ArticleId><ArticleId IdType="doi">10.3233/JHD-180309</ArticleId><ArticleId IdType="pii">JHD180309</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zoghbi HY OH. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000;23:217&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845064</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet. 2005;6(10):756&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16205715</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Paulson HL, Fischbeck KH. Trinucleotide repeat expansion in neurological disease. Ann Neurol. 1994;36(6):814&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">7998766</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner RB. Yeast and fungal prions. Cold Spring Harb Perspect Biol. 2016;8(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008071</ArticleId><ArticleId IdType="pubmed">27481532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Ho G, Sugama S, Takamatasu Y, Shimizu Y, Takenouchi T, et al. Evolvability of amyloidogenic proteins in human brain. J Alzheimers Dis. 2018;62(1):73&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5817905</ArticleId><ArticleId IdType="pubmed">29439348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Ho G, Takamatasu Y, Shimizu Y, Sugama S, Takenouchi T, et al. Evolvability and neurodegenerative disease: Antagonistic pleiotropy phenomena derived from amyloid aggregates. J Parkinsons Dis. 2018;8(3):405&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130413</ArticleId><ArticleId IdType="pubmed">30010144</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhlau M, Winkelmann J, Rujescu D, Giegling I, Kout-souleris N, Gaser C, et al. Variation within the Huntington&#x2019;s disease gene influences normal brain structure. PLoS One. 2012;7(1):e29809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250493</ArticleId><ArticleId IdType="pubmed">22235343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, Ding Y, Conrad AL, Cattaneo E, Epping E, Mathews K, et al. Sex-specific effects of the Huntington gene on normal neurodevelopment. J Neurosci Res. 2017;95(1-2):398&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729280</ArticleId><ArticleId IdType="pubmed">27870408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, Conrad A, Epping E, Mathews K, Magnotta V, Dawson JD, et al. Effect of trinucleotide repeats in the Huntington&#x2019;s gene on intelligence. EBioMedicine. 2018;31:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013750</ArticleId><ArticleId IdType="pubmed">29685790</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiuri T, Mocle AJ, Hung CL, Xia J, van Roon-Mom WM, Truant R. Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex. Hum Mol Genet. 2017;26(2):395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">28017939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno S. Gene duplication and the uniqueness of vertebrate genomes circa 1970-1999. Semin Cell Dev Biol. 1999;10(5):517&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10597635</ArticleId></ArticleIdList></Reference><Reference><Citation>Chastain PD, Sinden RR. CTG repeats associated with human genetic disease are inherently flexible. J Mol Biol. 1998;275(3):405&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson CE, Wang YH, Griffith JD, Sinden RR. Structural analysis of slipped-strand DNA (S-DNA) formed in (CTG)n. (CAG)n repeats from the myotonic dystrophy locus. Nucleic Acids Res. 1998;26(3):816&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC147324</ArticleId><ArticleId IdType="pubmed">9443975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinden RR, Potaman VN, Oussatcheva EA, Pearson CE, Lyubchenko YL, Shlyakhtenko LS. Triplet repeat DNA structures and human genetic disease: Dynamic mutations from dynamic DNA. J Biosci. 2002;27(1 Suppl 1):53&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927777</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavan J, Rossi ML, Bambara RA. Analysis of DNA replication intermediates suggests mechanisms of repeat sequence expansion. J Biol Chem. 2003;278(44): 42854&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12902352</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Liu J, Wu K, Chen Y. Insight into role of selection in the evolution of polyglutamine tracts in humans. PLoS One. 2012;7(7):e41167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405088</ArticleId><ArticleId IdType="pubmed">22848438</ArticleId></ArticleIdList></Reference><Reference><Citation>Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics. 2007;8:126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1896166</ArticleId><ArticleId IdType="pubmed">17519034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus-Perrotta C, Lagalwar S. Expansion, mosaicism and interruption: Mechanisms of the CAG repeat mutation in spinocerebellar ataxia type 1. Cerebellum Ataxias. 2016;3:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5118900</ArticleId><ArticleId IdType="pubmed">27895927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollereau B, Rzechorzek NM, Roussel BD, Sedru M, Van den Brink DM, Bailly-Maitre B, et al. Adaptive preconditioning in neurological diseases - therapeutic insights from proteostatic perturbations. Brain Res. 2016;1648(Pt B):603&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010532</ArticleId><ArticleId IdType="pubmed">26923166</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-beta fibrils from Alzheimer&#x2019;s disease clinical subtypes. Nature. 2017;541(7636):217&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>Theillet FX, Binolfi A, Bekei B, Martorana A, Rose HM, Stuiver M, et al. Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature. 2016;530(7588):45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan LE, Carr JK, Fluitt AM, Hoganson AJ, Moran SD, de Pablo JJ, et al. Structural motif of polyglutamine amyloid fibrils discerned with mixed-isotope infrared spectroscopy. Proc Natl Acad Sci USA. 2014;111(16):5796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000827</ArticleId><ArticleId IdType="pubmed">24550484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Berthelier V, Hamilton JB, O&#x2019;Nuallain B, Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry. 2002;41(23):7391&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner M, Gerhart J. Evolvability. Proc Natl Acad Sci USA. 1998;95(15):8420&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33871</ArticleId><ArticleId IdType="pubmed">9671692</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker C. Like father, like son. eLife. 2017;6.</Citation></Reference><Reference><Citation>Beer J, Masters CL, Beyreuther K. Cells from peripheral tissues that exhibit high APP expression are characterized by their high membrane fusion activity. Neurodegeneration. 1995;4(1):51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76(1):31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24798518</ArticleId></ArticleIdList></Reference><Reference><Citation>Trajkovic K, Jeong H, Krainc D. Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway. J Neurosci. 2017;37(37):9000&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5597981</ArticleId><ArticleId IdType="pubmed">28821645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodale V, Boggio R, Daldin M, Cariulo C, Spiezia MC, Byrne LM, et al. Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J Huntingtons Dis. 2017;6(4):349&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757651</ArticleId><ArticleId IdType="pubmed">29125493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. Like father like son. A fresh review of the inheritance of acquired characteristics. EMBO Rep. 2007;8(9):798&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973965</ArticleId><ArticleId IdType="pubmed">17767188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A. Transgenerational epigenetics: Integrating soma to germline communication with gametic inheritance. Mech Ageing Dev. 2017;163:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28093237</ArticleId></ArticleIdList></Reference><Reference><Citation>Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, et al. The most infectious prion protein particles. Nature. 2005;437(7056):257&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513539</ArticleId><ArticleId IdType="pubmed">16148934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambataro F, Pennuto M. Post-translational modifications and protein quality control in motor neuron and polyglu-tamine diseases. Front Mol Neurosci. 2017;10:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374214</ArticleId><ArticleId IdType="pubmed">28408866</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghdasi B, Ye K, Resnick A, Huang A, Ha HC, Guo X, et al. FKBP12, the 12-kDaFK506-binding protein, is aphys-iologic regulator of the cell cycle. Proc Natl Acad Sci USA. 2001;98(5):2425&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30154</ArticleId><ArticleId IdType="pubmed">11226255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugata H, Matsuo K, Nakagawa T, Takahashi M, Mukai H, Ono Y, et al. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles. Neurosci Lett. 2009;459(2):96&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun CS, Lee CC, Li YN, Yao-Chen Yang S, Lin CH, Chang YC, et al. Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. Sci Rep. 2015;5:14992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598856</ArticleId><ArticleId IdType="pubmed">26450664</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi T, Suzuki M, Fujikake N, Popiel HA, Kikuchi H, Futaki S, et al. Intercellular chaperone transmission via exosomes contributes to maintenance of protein home-ostasis at the organismal level. Proc Natl Acad Sci USA. 2015;112(19):E2497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434695</ArticleId><ArticleId IdType="pubmed">25918398</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita M, Wei J, Nakai M, Masliah E, Hashimoto M. Chaper-one and anti-chaperone: Two-faced synuclein as stimulator of synaptic evolution. Neuropathology. 2006;26(5):383&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17080714</ArticleId></ArticleIdList></Reference><Reference><Citation>Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet. 2001;68(2):313&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235265</ArticleId><ArticleId IdType="pubmed">11133364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi R, Tripathi N, Pallapati AR, Gaikar A, Bharatam PV, Roy I. Does N-terminal huntingtin function as a &#x2018;holdase&#x2019; for inhibiting cellular protein aggregation? FEBS J. 2018;285(10):1791&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">29630769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington&#x2019;s disease. Neuron. 2005;47(1):29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996546</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, et al. The Huntington&#x2019;s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA. 2000;97(12): 6763&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18731</ArticleId><ArticleId IdType="pubmed">10823891</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, Lowe S, et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene. 2006;25(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16278683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan AB, Zeitlin SO, Scrable H. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington&#x2019;s disease pathogenesis. Neurobiol Dis. 2006;24(2):419&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1803079</ArticleId><ArticleId IdType="pubmed">16978870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, et al. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Hunting-ton&#x2019;s disease. Sci Transl Med. 2014;6(268):268ra178.</Citation><ArticleIdList><ArticleId IdType="pubmed">25540325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Lin AC, Hong KY, Hu SH, Chen YL, Chen JY, et al. p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochem Int. 2011;58(2):145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21092747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA, et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer. J Biol Chem. 2012;287(33):28152&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431633</ArticleId><ArticleId IdType="pubmed">22715097</ArticleId></ArticleIdList></Reference><Reference><Citation>Checler F, Alves da Costa C. p53 in neurodegen-erative diseases and brain cancers. Pharmacol Ther. 2014;142(1):99&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">24287312</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazawa H. Polyglutamine diseases: A transcription disorder? Cell Mol Life Sci. 2003;60(7):1427&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">12943229</ArticleId></ArticleIdList></Reference><Reference><Citation>Waragai M, Lammers CH, Takeuchi S, Imafuku I, Udagawa Y, Kanazawa I, et al. PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum Mol Genet. 1999;8(6):977&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">10332029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuguchi M, Obita T, Serita T, Kojima R, Nabeshima Y, Okazawa H. Mutations in the PQBP1 gene prevent its interaction with the spliceosomal protein U5-15 kD. Nat Commun. 2014;5:3822.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781215</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci. 2016;19(4):623&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984042</ArticleId><ArticleId IdType="pubmed">26900923</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AJ, Nguyen AQ. Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. BMC Med Genet. 2011;12:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254080</ArticleId><ArticleId IdType="pubmed">22151998</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokeir MH. Investigation on Huntington&#x2019;s disease in the Canadian Prairies. II. Fecundity and fitness. Clin Genet. 1975;7(4):349&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">123838</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskenazi BR, Wilson-Rich NS, Starks PT. A Darwinian approach to Huntington&#x2019;s disease: Subtle health benefits of a neurological disorder. Med Hypotheses. 2007;69(6):1183&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17689877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE. Role of p53 in neurodegen-erative diseases. Neurodegener Dis. 2012;9(2):68&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3304514</ArticleId><ArticleId IdType="pubmed">22042001</ArticleId></ArticleIdList></Reference><Reference><Citation>Thion MS, Humbert S. Cancer: From wild-type to mutant huntingtin. J Huntingtons Dis. 2018;7(3):201&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087435</ArticleId><ArticleId IdType="pubmed">29889077</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa DC, de Oliveira GA, Cino EA, Soares IN, Rangel LP, Silva JL. Aggregation and prion-like properties of misfolded tumor suppressors: Is cancer a prion disease? Cold Spring Harb Perspect Biol. 2016;8(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5046694</ArticleId><ArticleId IdType="pubmed">27549118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungewitter E, Scrable H. Antagonistic pleiotropy and p53. Mech Ageing Dev. 2009;130(1-2):10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771578</ArticleId><ArticleId IdType="pubmed">18639575</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramdzan YM, Trubetskov MM, Ormsby AR, Newcombe EA, Sui X, Tobin MJ, et al. Huntingtin inclusions trigger cellular quiescence, deactivate apoptosis, and lead to delayed necrosis. Cell Rep. 2017;19(5):919&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28467905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey AS, La Spada AR. Therapy development in Huntington disease: From current strategies to emerging opportunities. Am J Med Genet A. 2018;176(4):842&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975251</ArticleId><ArticleId IdType="pubmed">29218782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, et al. Translating antisense technology into a treatment for Huntington&#x2019;s disease. Methods Mol Biol. 2018;1780:497&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">29856033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindqvist C, Laakkonen L, Albert VA. Polyglutamine variation in a flowering time protein correlates with island age in a Hawaiian plant radiation. BMC Evol Biol. 2007;7:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1939987</ArticleId><ArticleId IdType="pubmed">17605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Scala C, Tian X, Mehdiabadi NJ, Smith MH, Saxer G, Stephens K, et al. Amino acid repeats cause extraordinary coding sequence variation in the social amoeba Dictyostelium discoideum. PLoS One. 2012;7(9):e46150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460934</ArticleId><ArticleId IdType="pubmed">23029418</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael TP, Park S, Kim TS, Booth J, Byer A, Sun Q, et al. Simple sequence repeats provide a substrate for phenotypic variation in the Neurospora crassa circadian clock. PLoS One. 2007;2(8):e795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949147</ArticleId><ArticleId IdType="pubmed">17726525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemayel R, Chavali S, Pougach K, Legendre M, Zhu B, Boeynaems S, et al. Variable glutamine-rich repeats modulate transcription factor activity. Mol Cell. 2015;59(4):615&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543046</ArticleId><ArticleId IdType="pubmed">26257283</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo LQ, Martin-Morris LE, White K. Identification, secretion, and neural expression of APPL, a Drosophila protein similar to human amyloid protein precursor. J Neurosci. 1990;10(12):3849&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570036</ArticleId><ArticleId IdType="pubmed">2125311</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int. 2000;36(3): 175&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10676850</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni M, Cioni C. Fish synucleins: An update. Mar Drugs. 2015;13(11):6665&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663547</ArticleId><ArticleId IdType="pubmed">26528989</ArticleId></ArticleIdList></Reference><Reference><Citation>Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia&#x2019;s general population. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(8):864&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24038799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87(3):282&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4955276</ArticleId><ArticleId IdType="pubmed">27335115</ArticleId></ArticleIdList></Reference><Reference><Citation>Roan NR, Sandi-Monroy N, Kohgadai N, Usmani SM, Hamil KG, Neidleman J, et al. Semen amyloids participate in spermatozoa selection and clearance. eLife. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487211</ArticleId><ArticleId IdType="pubmed">28653619</ArticleId></ArticleIdList></Reference><Reference><Citation>Udd B, Krahe R. The myotonic dystrophies: Molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11(10):891&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">22995693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranum LP, Day JW. Dominantly inherited, non-coding microsatellite expansion disorders. Curr Opin Genet Dev. 2002;12(3):266&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilburn B, Rudnicki DD, Zhao J, Weitz TM, Cheng Y, Gu X, et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Hunt-ington&#x2019;s disease-like 2 mice. Neuron. 2011;70(3):427&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107122</ArticleId><ArticleId IdType="pubmed">21555070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, et al. Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell. 2016;167(3):789&#x2013;802 e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. The Huntington&#x2019;s Disease Collaborative Research Group. Cell. 1993;72(6):971&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>